(AIM: SAR)

11 July 2018

Sareum Holdings PLC

("Sareum” or “the Company”)

Director/ PDMR Shareholding

Sareum announces that Susan Parker, wife of Dr Stephen Parker, Sareum’s Chairman, purchased 609,756 of Ordinary Shares at a price of 0.82 pence per share yesterday. Following this transaction, Susan Parker now holds an interest of 1,284,028 Ordinary Shares in the company representing approximately 0.047% of the issued share capital of the Company. Dr. Parker and Susan Parker together now own a total of 1,745,977 Ordinary Shares, representing 0.064% of the Company’s issued share capital.

For further information, please contact:

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

 

WH Ireland Limited (Nominated Adviser)

 

Chris Fielding / James Sinclair-Ford

020 7220 1666

 

Hybridan LLP (Broker)

 

Claire Noyce

020 3764 2341

 

Citigate Dewe Rogerson (Media enquiries)

 

Shabnam Bashir/ Mark Swallow/ David Dible

020 7282 9571

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Susan Parker

2

Reason for the notification

a)

Position/status

PCA as wife of Chairman, Dr Stephen Parker, Sareum Holdings plc

b)

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Sareum Holdings plc

b)

LEI

213800PKERN2DY8FFM72

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of 0.025p each

 

 

 

GB00B02RFS12

b)

Nature of the transaction

Purchase of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

0.82p

609,756 shares

 

d)

Aggregated information

- Aggregated volume

-    Price

 

 

609,756

0.82p

e)

Date of the transaction

 10th July 2018

f)

Place of the transaction

London Stock Exchange, AIM

 

Notes for editors:

Sareum is a specialist drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and generating value through licensing them to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Its most advanced programme, SRA737, is a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology and undergoing Phase 2 clinical trials targeting a range of advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted therapy in genetically defined patients both as a monotherapy and in combination with other oncology and immuno-oncology drugs.

Sareum is also advancing programmes to develop novel tyrosine kinase 2 (TYK2) inhibitors in autoimmune diseases and cancers, and Aurora+FLT3 inhibitors in haematological cancers, which are in the IND-enabling preclinical and lead optimisation stages.

The Company's drug discovery technology platform (SKIL(R) - Sareum Kinase Inhibitor Library) is being applied to generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit www.sareum.co.uk

 

  • @Sareumplc Latest tweet

    TYK2 plays a key role in tumor development and survival in anaplastic large-cell lymphoma (ALCL), acording to a new… https://t.co/OHPCNHMYiW via @Sareumplc
    View more